Does the FDA approval of Pavblu mean it can treat my neovascular AMD?
Pavblu is a vascular endothelial growth factor (VEGF) inhibitor, a type of anti-VEGF drug. The FDA has approved Pavblu for treating neovascular (wet) age-related macular degeneration (AMD) 1. This means it is officially recognized as a treatment option for your condition. Pavblu works by blocking VEGF, a protein that promotes abnormal blood vessel growth and leakage in the eye, which are hallmarks of neovascular AMD.
What the research says
Pavblu is a biosimilar to the reference drug aflibercept (Eylea). A systematic review and meta-analysis of 11 studies involving over 4,000 participants found that aflibercept biosimilars show similar efficacy and safety to the reference drug in treating neovascular AMD 3. Specifically, there were no significant differences in visual acuity improvements or changes in retinal thickness between biosimilars and the original aflibercept 3. This suggests Pavblu should be as effective as Eylea for managing neovascular AMD.
Other anti-VEGF drugs, such as ranibizumab (Byooviz) and higher-dose aflibercept (Eylea HD), are also FDA-approved for neovascular AMD 68. These options give your doctor flexibility in choosing the best treatment for you. However, long-term anti-VEGF therapy does not prevent all vision loss. Research shows that subretinal fibrosis (scarring) develops in 40-50% of eyes after 5 years of treatment, and this is linked to worse visual outcomes 7. Additionally, some patients may have persistent disease activity despite anti-VEGF therapy, possibly due to VEGF-independent immune pathways 5. These findings highlight the importance of regular monitoring and individualized treatment plans.
While anti-VEGF therapy remains the standard of care, combining it with radiotherapy has been shown to increase the risk of vision loss compared to anti-VEGF alone 4. Therefore, current evidence supports anti-VEGF monotherapy as the primary approach for neovascular AMD.
What to ask your doctor
- Is Pavblu a good option for my specific type of neovascular AMD?
- How does Pavblu compare to other anti-VEGF drugs I might have used before, like Eylea or Lucentis?
- What is the recommended dosing schedule for Pavblu, and how often will I need injections?
- Are there any potential side effects or risks I should be aware of with Pavblu?
- How will we monitor my response to treatment and decide if adjustments are needed?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.